(PRWEB) March 18, 2005
Register now to attend Bioinvest 2005, the bioinformatics and biotechnology investment conference to be held at the DTI conference centre in London. The conference will be a showcase for emerging international biotechnology and bioinformatics companies. Investor pitches by companies will be focused on biotechnology companies in the morning, bioinformatics in the afternoon.
Northbank Communications is the communications partner for the new BioInvest 2005 Conference, an initiative of the UK Bioinformatics Forum and Oxfordshire Bioscience Network and Oxford Science Enterprise Centre, Said Business School. BioInvest 2005 is offering 50% off registration for a second company delegate and free entry for a third company delegate. First delegate rate is just Â£100. Includes refreshments, lunch and wine reception.
Networking drinks reception from 16.30 Â 19.00 at the conference venue.
Attendees will include seed fund managers, angel investors, venture capitalists, private equity managers and biotech/pharmaceutical executives, all looking for investment opportunities within the biotech and bioinformatics industries.
BioInvest 2005 allows investors to meet with leading and emerging biotechnology and informatics companies. Companies presenting include*:
Robert Feldman, CEO, Riotech Pharma
David Laskow Pooley, CEO, Surface Therapeutics
Yasmin Crawford, Director, Opal Healthcare Limited
Dr Dan Daly, Director, Lein Diagnostics
Christian Rohlff, CEO, Oxford Genome Sciences
Andrew Payne, CEO, Intellidos
Mark Tucker, CEO, G-Nostics
Will Saurin, CEO, Genomining
Adlan Hercus, Director, Synamatix
*Company appraisals available on the web site http://www.bioinvest2005.com
Bioinvest 2005 is a joint initiative of the UK Bioinformatics Forum and Oxfordshire Bioscience Network, and Oxford Science Enterprise Centre, Said Business School.
# # #